MISSISSAUGA, ON, January 12, 2026 – Novo Nordisk announced today that Health Canada has approved RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction…
Health Canada approves RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes
